Get the Stockscreener App
7.525
3.51%
0.255
After Hours:
7.30
-0.225
-2.99%
Aclarion Inc stock is traded at $7.525, with a volume of 57,604.
It is up +3.51% in the last 24 hours and up +16.13% over the past month.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
See More
Previous Close:
$7.27
Open:
$7.36
24h Volume:
57,604
Relative Volume:
0.73
Market Cap:
$4.48M
Revenue:
$49,300
Net Income/Loss:
$-6.27M
P/E Ratio:
-0.8278
EPS:
-9.09
Net Cash Flow:
$-5.38M
1W Performance:
+5.84%
1M Performance:
+16.13%
6M Performance:
+92.47%
1Y Performance:
-2.52%
1-Day Range:
$7.2012
$8.19
1-Week Range:
$6.79
$8.19
52-Week Range:
$0.7425
$562.68
Aclarion Inc Stock (ACON) Company Profile
Name
Aclarion Inc
Sector
Industry
Phone
833 275 2266
Address
8181 ARISTA PLACE, BROOMFIELD
Compare ACON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACON
Aclarion Inc
|
7.525 | 4.48M | 49,300 | -6.27M | -5.38M | -9.09 |
|
VEEV
Veeva Systems Inc
|
287.98 | 46.43B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
63.54 | 12.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
61.34 | 10.79B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
104.76 | 9.27B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
40.87 | 7.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Aclarion Inc Stock (ACON) Latest News
Contrasting Aclarion (NASDAQ:ACON) and Aeon Global Health (OTCMKTS:AGHC) - Defense World
Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site - Ortho Spine News
Aclarion (ACON) Expands CLARITY Trial with University of Miami H - GuruFocus
Aclarion Inc. Announces UHealth and University of Miami as New Site for CLARITY Clinical Trial Evaluating Nociscan for Chronic Low Back Pain - Nasdaq
Aclarion (NASDAQ:ACON) Upgraded by Wall Street Zen to Hold Rating - Defense World
Aclarion stock price target cut to $20 at Ascendiant Capital - Investing.com Australia
Aclarion stock price target cut to $20 at Ascendiant Capital By Investing.com - Investing.com India
Aclarion, Inc. (NASDAQ:ACON) Sees Large Drop in Short Interest - Defense World
Aclarion (NASDAQ:ACON) Trading Down 1.2% – Here’s Why - Defense World
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site - Ortho Spine News
USC Medical Center Joins Groundbreaking AI Trial to Revolutionize Chronic Back Pain Diagnosis - Stock Titan
Aclarion, Inc. SEC 10-Q Report - TradingView
Aclarion (ACON) Expands CLARITY Trial with Texas Back Institute - GuruFocus
Aclarion Announces Texas Back Institute as New CLARITY Trial Site - Ortho Spine News
Aclarion announces Texas Back Insitute as new CLARITY trial site - TipRanks
Aclarion Inc. Partners with Texas Back Institute for CLARITY Clinical Trial to Enhance Chronic Low Back Pain Treatment - Nasdaq
History Says Now Is the Time to Buy Nvidia Stock - The Globe and Mail
Aclarion Welcomes Advocate Health as CLARITY Trial Site - Ortho Spine News
Major Breakthrough: Advocate Health to Test AI-Powered Spine Pain Diagnostic in 300-Patient Trial - Stock Titan
Aclarion secures funding for pivotal CLARITY trial - MSN
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana - Ortho Spine News
Aclarion (ACON) Partners with Louisiana Spine Institute to Expan - GuruFocus
Aclarion announces agreement with the Spine Institute of Louisiana - TipRanks
Aclarion Expands Nociscan Access with Commercial Agreement at Spine Institute of Louisiana - Nasdaq
Revolutionary Spine Pain Technology Nociscan Achieves 97% Success Rate, Expands to 17 Medical Centers - Stock Titan
Aclarion stock hits 52-week low at $7.25 amid steep annual decline By Investing.com - Investing.com South Africa
Aclarion stock hits 52-week low at $7.25 amid steep annual decline - Investing.com
Aclarion, Inc. (NASDAQ:ACON) Short Interest Update - Defense World
Aclarion Inc Files For Mixed Shelf Of Up To $150 MlnSEC Filing - marketscreener.com
Aclarion Releases Updated Investor Presentation at Showcase - TipRanks
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025 - The Manila Times
Aclarion, Inc. to Present at Planet MicroCap Showcase: VEGAS 2025 on Chronic Low Back Pain Solutions - Nasdaq
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet ... - Bluefield Daily Telegraph
Aclarion's Revolutionary AI Approach to Chronic Back Pain: New Investor Strategy Revealed at MicroCap Vegas - Stock Titan
3 Reasons to Buy Amazon Stock Like There's No Tomorrow - The Globe and Mail
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis - Ortho Spine News
Aclarion's Nociscan Demonstrates Cost-Effectiveness and Improved Surgical Success Compared to Provocative Discography - Nasdaq
New Research: AI-Powered Spine Technology Cuts Patient Costs by $1,712, Boosts Surgery Success 10% - Stock Titan
NOCISCAN touted as lumbar pain diagnostic advance - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub - The Manila Times
Aclarion, Inc. SEC 10-K Report - TradingView
Aclarion stock hits 52-week low at $9.68 amid steep annual decline - Investing.com Canada
Aclarion stock hits 52-week low at $9.68 amid steep annual decline By Investing.com - Investing.com South Africa
Aclarion Inc Stock (ACON) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
2.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):